Provectus Biopharmaceuticals, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$336K
Cost of Revenue
—
Gross Profit
—
R&D
$2M
D&A
$2K
Operating Income
$-5M
EBITDA
$-5M
Interest Expense
$5K
Interest Income
—
Other Income/Expense
$-205K
Pretax Income
$-6M
Tax Provision
—
Net Income
$-5M
Gross Margin
—
Operating Margin
-1575.3%
Net Margin
-1615.8%
Deferred Tax Assets
—
DTA Valuation Allowance
$47M
Tax Credit Carryforwards
$4M
NOL Carryforwards
$31M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-5.1%
Operating Lease Cost
$48K
Revenue YoY Variation
-45.5%
Income YoY Variation
-16.8%